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 The Introduction and Development 
of Clinical PET in the United Kingdom 
 Michael  Maisey 
 Twenty-fi ve years ago (half the life of the BNMS) in 1990 clinical PET imaging 
began to be accepted as an important clinical diagnostic tool (Fig.  14.1 ).
 There were then approximately 60 pet centres in the United States 20 in Japan 
and even six in Belgium however there was not a single clinical PET service in the 
United Kingdom in spite of the fact that the Medical Cyclotron and PET unit at the 
Hammersmith Hospital was at the cutting edge of research in this area. 
 In 1990, during a post prandial stroll back to our hotel during EANM conference, 
Desmond Croft (Gastroenterologist and head of Nuclear Medicine at St Thomas’ 
hospital) and I discussed the possibility of establishing the fi rst clinical PET Centre 
in the UK. Guys and St Thomas’ Medical schools had been united in 1984 to form 
the joint United Medical and Dental Schools (UMDS) but the two hospitals remained 
separate entities (although later merging to form one hospital trust) We felt at the 
time that a single PET centre supported by both hospitals and based in the medical 
school would make it more likely that we could raise the necessary support and 
critically the funding. 
 Looking back to that time Twenty-fi ve years ago it is interesting to note that the 
proposal was based mainly on neuropsychiatric indications (predominantly to iden-
tify pre-surgical sites of focal epilepsy and early diagnosis of Alzheimer’s disease) 
and Cardiological applications (viability of ischaemic compromised myocardium) 
there was some early evidence from the United States and elsewhere that applica-
tions in cancer might assume a greater importance which at that time was restricted 
mainly to brain tumour recurrence and some early work in staging and recurrent 
Lung cancer. 
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 The concept we discussed that evening was to develop a clinical PET centre which 
was both a clinical service and a clinical research centre which would encompass a 
small medical cyclotron with a radiochemistry laboratory, with clinical PET scan 
imaging facilities at Guys hospital and St Thomas’ Hospital with the whole centre 
functioning as a single entity. This plan seemed to make the likelihood of success 
higher as initial estimates suggested that around £5 million would need to be raised. 
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 The proposals were presented to UMDS and the boards of both Hospital 
Trusts and after considerable discussion the plan was supported by both the hos-
pitals and Medical School with the new centre in the newly created division of 
Radiological Sciences. At that time Trusts were very separate from the academic 
school and were more risk adverse. The absolute ‘proviso’ was that we must 
raise the capital funding and the centre should be fi nancially self supporting with 
all staff and running costs to be covered by charging for scan referrals, selling 
radiotracers from the radiochemistry unit as well as grants supporting clinical 
research projects. 
 After an initial period of planning and costing, with signifi cant support from the 
Hammersmith PET group, even though there were some who did not believe that it 
was appropriate to use PET for clinical purposes! Early funding was raised from 
several sponsors before a formal fundraising program was established. We were 
fortunate in persuading the ex deputy prime minister under Margaret Thatcher-Lord 
William “every Prime Minister should have a Willie” Whitelaw to chair the appeal 
aptly named ‘The Living Image appeal’ Fig.  14.2 .
 The fi rst formal meeting of which took place in December 1991 in the House of 
Lords! Lord Whitelaw proved to be an excellent chairman and within 6 months 
approximately 2.3 million had been raised and work to establish the centre was 
underway. The cyclotron itself was to be installed in the basement of St Thomas’s 
Hospital with an imaging centre on the ground fl oor above and the second unit was 
incorporated in the physics Department below the nuclear medicine department at 
 Fig. 14.2  Ex deputy prime minister under Margaret Thatcher-Lord William Whitelaw with 
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Guys Hospital. Figure  14.3 shows St Thomas Hospital overlooking the river Thames 
on the left and Guy’s Hospital tower on the right (Fig.  14.4 ).
 During 1994 the ‘Living image appeal’ was discontinued as the total sum of £5 
million had been reached and the centre was a going concern with signifi cant exter-
nal funded referrals and further income raised by selling cyclotron produced radio-
pharmaceuticals to increasing numbers of developing clinical PET facilities around 
the country. Added to this was the clinical research grants which had been gained. 
 It is interesting to note that by the end of the fi rst year approximately 28 % of the 
clinical scans were referrals for cancer; diagnosis and treatment monitoring and by 
1994 the fi gure had risen to 48 % currently the fi gure runs at over 90 %. Around half 
of the scans were for clinical purposes and approximately half for funded clinical 
research projects and all staff and running costs were being covered by the income 
from these sources. On the basis of our original projections (Neuropsychiatric and 
Cardiac) it has to be doubted whether the project would have been fi nancially via-
ble, but that is now history. 
 It is diffi cult to overestimate the importance of an effective team, with no formal 
training, to run a unit of this type, both then and now. Everybody: administrative, 
technical, radiographers scientists (Physics, Chemists and Computer scientists) as 
well as doctors, were essential and remain essential to the effective working of a 
unit of this type. Twenty-fi ve years ago it was a very steep learning curve for every-
one involved, particularly for the medical staff for whom formal training in clinical 
PET was not generally available. Also there was little available in the literature this 
meant learning and reporting the appearances of abnormal PET scans equally 
important was learning the range of normal variations of the physiological 




distribution of tracer. A signifi cant innovation in organisation was the blind double 
reading whereby each scan was read independently, disagreements discussed and 
agreed upon or referred to a third reader. I believe using this method we moved up 
the learning curve more rapidly and avoided many potentially serious errors: an 
arrangement which continues today. 
 Although we had expected to be mainly involved in neuropsychiatric and 
Cardiological applications it became clear that cancer would form a huge amount of 
the workload of clinical PET and this has continued. It was always expected that a 
range of biological traces would be involved however the fundamental tracer Fluoro- 
deoxy Glucose (FDG) proved to be by far the most important and remains so today. 
 Gradually with the clinical success from referrals many other centres invested in 
PET imaging devices, as long as it was possible to obtain the appropriate tracers with-
out the necessity of establishing at cyclotron and a radiochemistry unit the costs could 
be kept down there are now medical cyclotrons and diagnostic PET units in the UK 
many of which are commercial subcontracted to NHS of which about half are mobile 
systems including two suppliers of PET tracers (FDG, F-Choline and 18F Fluoride). 
 Anatomic localisation of the sites of tracer uptake in around 10 % of the cases 
remained a clinical problem for reporting scans. Early research work, in conjunc-
tion with our Radiological sciences computer imaging group, combining PET 
images with more conventional CT and MRI images Fig.  14.5 based on computer- 
generated image fusion was productive.
 This image fusion, of course, was later taken on by the commercial manufactur-
ers incorporating CT and later MR into the imaging device itself (PET/CT) which 
 Fig. 14.4  HRH Prince Charles at the formal opening of the Clinical PET centre. Prof Michael 
Maisey and Dr Tony Gee, Radio chemist demonstrates the equipment to Prince Charles on the  right 
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permitted accurate localisation as well as quicker attenuation correction, 8 patients/
day was then maximum throughput, now about twice that rate is possible. The vast 
majority of PET devices are now PET CT devices and a few, including a new one at 
the Guys St Thomas’s PET centre, incorporate MRI (PET/MR). This has also meant 
that non radiology trained Nuclear Medicine staff have had to undertake more for-
mal training in cross sectional anatomical imaging. 
 The future remains exciting with further development of specifi c radio traces, in 
addition to FDG: F-Choline is routine for prostate cancer, 68Gallium for neuroen-
docrine tumours and 68Gallium PSMA has just become commercially available. An 
area that we thought at the time would be important; combined PET and MR spec-
troscopy has not as yet delivered any signifi cant advances. 
 In 2015 25 years after the start of the fi rst UK PET centre the whole unit has 
been refurbished with 2 new PET/CT scanners and a high fi eld 3 T PET/MR 
scanner for clinical and basic research including spectroscopy. There is a PET /
CT planned for the new cancer centre in 2016. In addition cyclotron and chem-
istry laboratories are being refurbished and is now probably the best equipped 
and most productive unit in the UK and I’m proud to have been associated with 
the onset and introduction of clinical PET into the United Kingdom. Research 
continues to be of great importance and a short selection of some key research 
publications below. 
 Fig. 14.5  PET and CT 
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 Michael  Maisey  After completing an MD based on an 131 biological assay for long acting thy-
roid-stimulating (LATS) I went to the United States in 1970 as a trainee Fellow at the Johns 
Hopkins Hospital in Baltimore in Nuclear Medicine. Johns Hopkins Nuclear Medicine under 
Henry Wagner was regarded at that time as the leading training centre for nuclear medicine world-
wide. After spending 2 years there and gaining the American Boards in Nuclear Medicine I 
returned in 1972 to be appointed consultant in Nuclear Medicine at Guy’s Hospital to establish the 
fi rst nuclear medicine department in that hospital. 
 After 12 years in this post he was appointed Professor of Radiological Sciences with a remit to 
organise undergraduate and postgraduate teaching and research in diagnostic imaging into one 
organisation with strong science base. A signifi cant early achievement was to obtain the fi rst high 
fi eld strength MRI machine and to give opportunities for the skills and roles of non-medical scien-
tists within the discipline. In 1992 the U.K.’s fi rst clinical PET centre for diagnosis and research 
was established within the division of radiological sciences. 
 Amongst other things I was president of BNMS and later the British Institute of Radiology 
retiring in 2003. 
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